|Videos|December 21, 2017

Dr. Kim Discusses PD-L1 as a Biomarker in Lung Cancer

Edward S. Kim, MD, chair, Solid Tumor Oncology and Investigational Therapeutics, Donald S. Kim Distinguished Chair for Cancer Research, Levine Cancer Institute, Carolinas HealthCare System, discusses PD-L1 as a biomarker in lung cancer.

Although PD-L1 has been contested as a reliable biomarker in lung cancer, Kim says that it is useful for selecting patients to receive frontline immunotherapy.

Stay up to date on the most recent and practice-changing oncology data

Subscribe Now!

Dr. Kim Discusses PD-L1 as a Biomarker in Lung Cancer

Newsletter

Related Content

Dr Braunstein on the FDA Approval of Subcutaneous Daratumumab With VRd For Newly Diagnosed Multiple Myeloma

Dr Garcia-Manero on the GLORA-4 Trial of Lisaftoclax Plus Azacitidine in High-Risk MDS

Dr Bardia on the Efficacy of Giredestrant in ER+, HER2-Negative Early Breast Cancer

Dr Callander on the Management of CAR T-Cell Therapy–Associated Complications in Myeloma

Dr Felip on Updated Efficacy Data From the Phase 3 MARIPOSA Trial

Latest CME

Medical Crossfire®: Bridging Evidence to Practice in AML…Updates on FLT3, IDH1/2, Maintenance, Combos, and Clinical Trials

Community Oncology Connections™: Optimizing SCLC Treatment Strategies and Managing Adverse Events Across Disease Stages | South Carolina

Personalized Management in NSCLC: Strategies for Early Detection, Molecular Testing, and Targeted Therapies | Kansas

Community Oncology Connections™: Beyond Primary End Points—Digging Into Randomized and Real-World Data to Guide Challenging Treatment Decisions in HR+/HER2− Metastatic Breast Cancer | Washington State Medical Oncology Society

Personalized Management in NSCLC: Strategies for Early Detection, Molecular Testing, and Targeted Therapies | Wyoming and Montana

Live Tumor Board: Squamous Cell Carcinoma of the Head & Neck – Post-CRT Decisions in the Locally Advanced Setting

Striking the Right Nerve: Managing Cancer Associated LEMS in Lung Cancer Patients

Show Me the Data™: Bridging Clinical Gaps Along the Continuum From Resectable, Early Stage to Advanced Gastric/Gastroesophageal Junction Cancers

Medical Crossfire®: Expert Interpretations of the Latest Data in CLL Management – Understanding the Impact of Optimal Treatment Selection on Patient Outcomes

Virtual Testing Board: Digging Deeper on Your Testing Reports to Elevate Patient Outcomes in Advanced Non–Small Cell Lung Cancer

Medical Crossfire® – From Diagnostic Dilemmas to Potential Treatment Breakthroughs: Exploring Novel Targets for Extrapulmonary Neuroendocrine Carcinomas

Addressing Unmet Needs in HER2+ Metastatic BTC

Community Practice Connections™: Tailored Treatment Approaches for Older Patients With Advanced HR+/HER2– Breast Cancer

Community Practice Connections™: Optimizing Treatment Outcomes and Preserving Fertility in Premenopausal HR+ Breast Cancer

Community Practice Connections™: Empowering Interventional Radiologists in the Emerging Era of Oncolytic Immunotherapies for Melanoma

Medical Crossfire®: Harnessing the Power of Modern Therapies in Newly Diagnosed Multiple Myeloma

Medical Crossfire®: Expert Perspectives on Targeting c-Met Overexpression and 𝘔𝘌𝘛 Genomic Alterations in NSCLC – Unveiling the Complexities of 𝘔𝘌𝘛 Dysregulation

Evolving Treatment Strategies in Pancreatic Cancer: Current Standards, Emerging Targets, and the Role of Molecular Testing

PER Tumor Board®: Applying Recent Advances to Transform the Treatment Paradigm in SCLC—Expert Perspectives on New Approvals and Emerging Strategies

Medical Crossfire®: Integrating Next-Generation Endocrine Targeting Therapies to Improve Outcomes for Patients With HR+/HER2- Breast Cancer

Medical Crossfire®: Improving Patient Outcomes in Myeloproliferative Neoplasms With Novel Therapeutic Approaches

Medical Crossfire®: Precision Medicine in Glioma Treatment — Integration of Molecular Profiling to Inform Targeted Therapies

Cases & Conversations™: Transforming AML Care—Precision Strategies, Evolving Therapies, and Clinical Insights

Tumor Board: Expert Insights on Managing Classical 𝘌𝘎𝘍𝘙 Mutations, 𝘌𝘎𝘍𝘙 Exon 20 Insertions, and Atypical 𝘌𝘎𝘍𝘙 Mutations in Metastatic NSCLC

Personalized Management in NSCLC: Strategies for Early Detection, Molecular Testing, and Targeted Therapies | New Mexico

Community Oncology Connections™: Optimizing SCLC Treatment Strategies and Managing Adverse Events Across Disease Stages | North Carolina

A Breath of Strength: Managing Cancer Associated LEMS and Lung Cancer as One

19th Annual New York GU Cancers Congress™

From Bench to Bedside: Paradigm Shifts in HER2+ Metastatic BTC Treatment

Proactive Adverse Event Management for HER2+ BTC Treatments

A Case-Guided Discussion on Managing Immune Thrombocytopenic Purpura (ITP)

GI Tumor Board—Applying Recent Advances in Biomarker Testing and Treatment in Metastatic Colorectal Cancer

Cases and Conversations™: Sorting Through the Expanding Treatment Options for Patients with Relapsed/Refractory Multiple Myeloma

Trending on OncLive

FDA Approves Daratumumab and Hyaluronidase Plus VRd for Newly Diagnosed Multiple Myeloma

NP-G1-044 Receives FDA Orphan Drug Designation for Pancreatic Cancer

PD-L1 Expression Is More Predictive of Response to Pembrolizumab on Metastatic Sites in High-Grade Serous Ovarian Cancer

Ixazomib-Based Regimens Expand Options in Relapsed/Refractory Multiple Myeloma

Meta-Analysis Characterizes Nivolumab/Ipilimumab Hyperprogression in Renal Medullary Carcinoma